Elanco Animal Health Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
ELAN$26.76-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows from Operating Activities | ||
| Net (loss) income | $(18) | $6 |
| Adjustments to reconcile net (loss) income to cash flows from operating activities: | ||
| Depreciation and amortization | 328 | 350 |
| Stock-based compensation expense | 25 | 21 |
| Asset impairment and write-down charges | 61 | — |
| Changes in operating assets and liabilities, net of acquisitions and divestitures | (155) | (473) |
| Other non-cash operating activities, net | (39) | 12 |
| Net Cash Provided by (Used for) Operating Activities | 202 | (84) |
| Cash Flows from Investing Activities | ||
| Net purchases of property and equipment and software | (58) | (66) |
| Cash paid for acquisitions | (5) | (16) |
| Proceeds from sale of Shawnee and Speke facilities (see Note 4) | 66 | — |
| Purchases of intangible assets | — | (14) |
| Other investing activities, net | 1 | (2) |
| Net Cash Provided by (Used for) Investing Activities | 4 | (98) |
| Cash Flows from Financing Activities | ||
| Proceeds from Revolving Credit Facility | 50 | 250 |
| Repayments of Revolving Credit Facility | (250) | — |
| Proceeds from Securitization Facility | 170 | — |
| Repayments of Securitization Facility | (50) | — |
| Repayments of long-term borrowings | (25) | (32) |
| Other financing activities, net | (15) | (5) |
| Net Cash (Used for) Provided by Financing Activities | (120) | 213 |
| Effect of exchange rate changes on cash and cash equivalents | (22) | (9) |
| Net increase in cash and cash equivalents | 64 | 22 |
| Cash and cash equivalents – beginning of period | 352 | 345 |
| Cash and cash equivalents – end of period | $416 | $367 |
2024 Q2 Form 10-Q | 8
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.